Cited by 395Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapyCancer Treatment and Pharmacology

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Monk, Bradley J., Herzog, Thomas J., Kaye, Stanley B., Krasner, Carolyn N., Vermorken, Jan B., Muggia, Franco M., Pujade-Lauraine, Eric, Lisyanskaya, Alla S., Makhson, Anatoly N., Rolski, Janusz, Gorbounova, Vera A., Ghatage, Prafull, Bidzinski, Mariusz, Shen, Keng, Ngan, Hextan Yuen-Sheung, Vergote, Ignace B., Nam, Joo-Hyun, Park, Youn Choi, Lebedinsky, Claudia A., Poveda, Andrés M.·2010·Journal of Clinical Oncology

DOI 10.1200/jco.2009.25.4037

Open this paper in CoChat — free account

Abstract

Purpose: The objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy. Patients and Methods: Women ≥ 18 years, stratified by performance status (0 to 1 v 2) and platinum sensitivity, were randomly assigned to receive an intravenous infusion of PLD 30 mg/m 2 followed by a 3-hour infusion of trabectedin 1.1 mg/m 2 every 3 weeks or PLD 50 mg/m 2 every 4 weeks. The primary end point was progression-free survival (PFS) by independent radiology assessment. Results: Patients (N = 672) were randomly assigned to trabectedin/PLD (n = 337) or PLD (n = 335). Median PFS was 7.3 months with trabectedin/PLD v 5.8 months with PLD (hazard ratio, 0.79; 95% CI, 0.65 to 0.96; P = .0190). For platinum-sensitive patients, median PFS was 9.2 months v 7.5 months, respectively (hazard ratio, 0.73; 95% CI, 0.56 to 0.95; P = .0170). Overall response rate (ORR) was 27.6% for trabectedin/PLD v 18.8% for PLD (P = .0080); for platinum-sensitive patients, it was 35.3% v 22.6% (P = .0042), respectively. ORR, PFS, and overall survival among platinum-resistant patients were not statistically different. Neutropenia was more common with trabectedin/PLD. Grade 3 to 4 transaminase elevations were also more common with the combination but were transient and noncumulative. Hand-foot syndrome and mucositis were less frequent with trabectedin/PLD than with PLD alone. Conclusion: When combined with PLD, trabectedin improves PFS and ORR over PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.25.4037

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Global cancer statistics
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
Gordon, A. N., Fleagle, J., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, Á. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,212

Show all 30 references

Research works printed but not linked: 2

Takahashi N, 2001, Clin Cancer Res, 7, 3251
Donald S, 2003, Cancer Res, 63, 5902

Sorted by citations

Ovarian cancer
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ledermann, J. A., Raja, F. A., Fotopoulou, C., González-Martı́n, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,119
A Review on Antibiotic Resistance: Alarm Bells are Ringing
Zaman, S. B., Hussain, M. A., Nye, R., Mehta, V., Mamun, K. T., & Hossain, N. (2017) · Cureus · doi:10.7759/cureus.1403 · Cited by 866
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 887
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S. T., Kumar, L., & Friedlander, M. L. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 564
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
Self-citation
“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
Davis, A., Tinker, A. V., & Friedlander, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.038 · Cited by 433
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment
Allavena, P., & Mantovani, A. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04515.x · Cited by 399
Tumor-Associated Macrophages: Implications in Cancer Immunotherapy
Petty, A. J., & Yang, Y. (2017) · Immunotherapy · doi:10.2217/imt-2016-0135 · Cited by 369
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. L. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12614 · Cited by 332
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
Hanker, L., Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, É., Ray-Coquard, I., Sehouli, J., Harter, P., & du Bois, A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds203 · Cited by 327
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Crum, C. P., & Friedlander, M. L. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60025-3 · Cited by 327
Therapeutic strategies in epithelial ovarian cancer
Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-14 · Cited by 315
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Monk, B. J., Poveda, A. M., Vergote, I. B., Raspagliesi, F., Fujiwara, K., Bae, D., Oaknin, A., Ray-Coquard, I. L., Provencher, D. M., Karlan, B. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70244-x · Cited by 301
Self-citation
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
Wilson, M. K., Pujade-Lauraine, É., Aoki, D., Mirza, M. R., Lorusso, D., Oza, A. M., du Bois, A., Vergote, I. B., Reuß, A., Bacon, M. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw663 · Cited by 291
Self-citation
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
Luvero, D., Milani, A., & Ledermann, J. A. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014544121 · Cited by 262
Pegylated Liposomal Doxorubicin: A Review of its use in Metastatic Breast Cancer, Ovarian Cancer, Multiple Myeloma and AIDS-Related Kaposiʼs Sarcoma
Duggan, S. T., & Keating, G. M. (2011) · Drugs · doi:10.2165/11207510-000000000-00000 · Cited by 234
Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer
Poveda, A. M., Kaye, S. B., Mccormack, R. T., Wang, S., Parekh, T. V., Ricci, D. S., Lebedinsky, C. A., Tercero, J. C., Zintl, P., & Monk, B. J. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.028 · Cited by 179
Self-citation
Unique features of trabectedin mechanism of action
Larsen, A. K., Galmarini, C. M., & D’Incalci, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2918-1 · Cited by 174
Anti-angiogenic agents in ovarian cancer: past, present, and future
Monk, B. J., Minion, L. E., & Coleman, R. L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw093 · Cited by 171
Self-citation
Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics
Le, V. H., Inai, M., Williams, R. M., & Kan, T. (2014) · Natural Product Reports · doi:10.1039/c4np00051j · Cited by 167
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
Poveda, A. M., Vergote, I. B., Tjulandin, S., Kong, B., Roy, M., Chan, S. Y. T., Filipczyk−Cisarż, E., Hagberg, H., Kaye, S. B., Colombo, N., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq352 · Cited by 162
Self-citation
The systemic treatment of recurrent ovarian cancer revisited
Baert, T., Ferrero, A., Sehouli, J., O’Donnell, D. M., González-Martı́n, A., Joly, F., van der Velden, J., Blecharz, P., Tan, D. S. P., Querleu, D., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.015 · Cited by 157
Management strategies for recurrent platinum-resistant ovarian cancer
Naumann, R. W., & Coleman, R. L. (2011) · Drugs · doi:10.2165/11591720-000000000-00000 · Cited by 152
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives
Mabuchi, S., Sugiyama, T., & Kimura, T. (2016) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2016.27.e31 · Cited by 153
Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology
Kovic, B., Jin, X., Kennedy, S. A., Hylands, M., Pędziwiatr, M., Kuriyama, A., Gomaa, H. A., Lee, Y., Katsura, M., Tada, M., et al. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.4710 · Cited by 144
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
Cesne, A. L., Cresta, S., Maki, R. G., Blay, J., Verweij, J., Poveda, A. M., Casali, P. G., Balañá, C., Schöffski, P., Grosso, F., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.012 · Cited by 140
Self-citation
Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review
Péron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 132
Bevacizumab in ovarian cancer: A critical review of phase III studies
Rossi, L., Verrico, M., Zaccarelli, E., Papa, A., Colonna, M., Strudel, M., Vici, P., Bianco, V., & Tomao, F. (2016) · Oncotarget · doi:10.18632/oncotarget.13310 · Cited by 112
Marine Invertebrate Metabolites with Anticancer Activities: Solutions to the “Supply Problem”
Gomes, N. G. M., Dasari, R., Chandra, S., Robert Kiss, A., & Kornienko, A. (2016) · Marine Drugs · doi:10.3390/md14050098 · Cited by 109
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
Conte, G. D., Sessa, C., von Moos, R., Viganò, L., Digena, T., Locatelli, A., Gallerani, E., Fasolo, A., Tessari, A., Cathomas, R. L., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.345 · Cited by 104
Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
Banerjee, S. N., Oza, A. M., Birrer, M. J., Hamilton, E. P., Hasan, J., Leary, A. F., Moore, K. N., Maćkowiak-Matejczyk, B., Pikiel, J., Ray-Coquard, I., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy023 · Cited by 102
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Crum, C. P., & Friedlander, M. L. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2015.06.007 · Cited by 103
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, É., Park, Y. C., Parekh, T. V., & Poveda, A. M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.001 · Cited by 95
Self-citation
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
Monk, B. J., Brady, M. F., Aghajanian, C. A., Lankes, H. A., Rizack, T., Leach, J. W., Fowler, J. M., Higgins, R. V., Hanjani, P., Morgan, M. A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx049 · Cited by 94
Self-citation
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study
Monk, B. J., Blessing, J. A., Street, D. G., Muller, C. Y., Burke, J. J., & Hensley, M. L. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.019 · Cited by 93
Self-citation
Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach
Tomao, F., Papa, A., Rossi, L., Strudel, M., Vici, P., Russo, G. L., & Tomao, S. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-48 · Cited by 93
Chemotherapy in epithelial ovarian cancer
Pignata, S., Cannella, L., Leopardo, D., Pisano, C., Bruni, G. S., & Facchini, G. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.026 · Cited by 91
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO)
Lortholary, A. H., Largillier, R., Weber, B. E., Gladieff, L., Alexandre, J., Durando, X., Slama, B., Dauba, J., Paraiso, D., & Pujade-Lauraine, É. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr149 · Cited by 91
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Pignata, S., Scambia, G., Bologna, A., Signoriello, S., Vergote, I. B., Wagner, U. A. G., Lorusso, D., Murgia, V., Sorio, R., Ferrandina, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.4293 · Cited by 87
Self-citation
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 85
Optimal treatment for relapsing ovarian cancer
Ledermann, J. A., & Kristeleit, R. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq377 · Cited by 83
Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum‐free interval: Myth or reality?
Tomao, F., D’Incalci, M., Biagioli, E. C., Peccatori, F. A., & Colombo, N. (2017) · Cancer · doi:10.1002/cncr.30830 · Cited by 82
Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
Soares, D. G., Machado, M. S., Rocca, C. J., Poindessous, V., Ouaret, D., Sarasin, A. R., Galmarini, C. M., Henriques, J. A. P., Escargueil, A. E., & Larsen, A. K. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0252 · Cited by 81
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
Cesne, A. L., Yovine, A. J., Blay, J., Delaloge, S., Maki, R. G., Misset, J. L., Frontelo, P., Nieto, A., Jiao, J. J., & Demetri, G. D. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9662-0 · Cited by 78
Avelumab (Anti-PD-L1) in Platinum-Resistant/Refractory Ovarian Cancer: JAVELIN Ovarian 200 Phase III Study Design
Pujade-Lauraine, É., Fujiwara, K., Dychter, S. S., Devgan, G., & Monk, B. J. (2018) · Future Oncology · doi:10.2217/fon-2018-0070 · Cited by 76
Self-citation
Trabectedin
Carter, N. J., & Keam, S. J. (2010) · Drugs · doi:10.2165/11202860-000000000-00000 · Cited by 74
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
Herzog, T. J., Armstrong, D. K., Brady, M. F., Coleman, R. L., Einstein, M. H., Monk, B. J., Mannel, R. S., Thigpen, J. T., Umpierre, S. A., Villella, J., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.008 · Cited by 72
Self-citation
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
Madariaga, A., Lheureux, S., & Oza, A. M. (2019) · Cancers · doi:10.3390/cancers11030416 · Cited by 73
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr441 · Cited by 69
Ovarian cancer relapse: From the latest scientific evidence to the best practice
Luvero, D., Plotti, F., Aloisia, A., Montera, R., Terranova, C., Nardone, C. D. C., Scaletta, G., Lopez, S., Miranda, A., Capriglione, S., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.014 · Cited by 68
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study
Monk, B. J., Ghatage, P., Parekh, T. V., Henitz, E. D., Knoblauch, R. E., Matos-Pita, A. S., Nieto, A., Park, Y. C., Cheng, P. S., Li, W., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv071 · Cited by 66
Self-citation
Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: A therapeutic implication
Suh, D. H., Kim, H. S., Kim, B., & Song, Y. S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.011 · Cited by 64
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)
Romano, M., Frapolli, R., Zangarini, M., Bello, E., Porcu, L., Galmarini, C. M., García‐Fernández, L., Cuevas, C., Allavena, P., Erba, E., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28213 · Cited by 63
Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer
Guo, Z., Wang, H., Meng, F., Li, J., & Zhang, S. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0613-y · Cited by 64
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
Mantia-Smaldone, Edwards, & Vlad, A. (2010) · Cancer Management and Research · doi:10.2147/cmar.s8759 · Cited by 63
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products
Trendowski, M. R. (2015) · Drugs · doi:10.1007/s40265-015-0489-4 · Cited by 67
Therapeutic Impact of Nanoparticle Therapy Targeting Tumor-Associated Macrophages
Penn, C. A., Yang, K., Zong, H., Lim, J. Y., Cole, A., Yang, D., Baker, J. R., Goonewardena, S. N., & Buckanovich, R. J. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0688 · Cited by 64
Drug-induced liver injury in Oncology
Ricart, A. D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx158 · Cited by 62
Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin
Poveda, A. M., Ray-Coquard, I. L., Romero, I., López‐Guerrero, J. A., & Colombo, N. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.08.001 · Cited by 60
Self-citation
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
Kaye, S. B., Colombo, N., Monk, B. J., Tjulandin, S., Kong, B., Roy, M., Chan, S. Y. T., Filipczyk−Cisarż, E., Hagberg, H., Vergote, I. B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq353 · Cited by 60
Self-citation
From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds
Wang, E., Sorolla, M. A., Krishnan, P. D. G., & Sorolla, A. (2020) · Biomolecules · doi:10.3390/biom10020248 · Cited by 65
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
Lawrie, T. A., Bryant, A., Cameron, A. L., Gray, E., & Morrison, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006910.pub2 · Cited by 59
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
Liu, J. F., Burris, H. A., Wang, J. S.-Z., Barroilhet, L. M., Gutierrez, M. E., Wang, Y., Vaze, A., Commerford, R., Royer‐Joo, S., Choeurng, V., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.09.023 · Cited by 58
Targeting Signaling Pathways in Epithelial Ovarian Cancer
Smolle, E., Taucher, V., Pichler, M., Petru, E., Lax, S., & Haybaeck, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14059536 · Cited by 61
Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
Ray-Coquard, I. L., Cibula, D., Mirza, M. R., Reuß, A., Ricci, C., Colombo, N., Koch, H., Goffin, F., González-Martı́n, A., Ottevanger, P. B., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32606 · Cited by 57
Cytotoxic and targeted therapy for hereditary cancers
Iyevleva, A. G., & Имянитов, Е. Н. (2016) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-016-0057-2 · Cited by 57
Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone
Krasner, C. N., Poveda, A. M., Herzog, T. J., Vermorken, J. B., Kaye, S. B., Nieto, A., Claret, P. L., Park, Y. C., Parekh, T. V., & Monk, B. J. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.06.034 · Cited by 53
Self-citation
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin
Erriquez, J., Becco, P., Olivero, M., Ponzone, R., Maggiorotto, F., Ferrero, A., Scalzo, M. S., Canuto, E. M., Sapino, A., di Cantogno, L. V., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.025 · Cited by 52
Pegylated liposomal doxorubicin in the management of ovarian cancer
Staropoli, N., Ciliberto, D., Botta, C., Fiorillo, L., Grimaldi, A., Lama, S., Caraglia, M., Salvino, A., Tassone, P., & Tagliaferri, P. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28557 · Cited by 52
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer
Verschraegen, C. F., Czok, S., Muller, C. Y., Boyd, L. R., Lee, S.-J., Rutledge, T. L., Blank, S. V., Pothuri, B., Eberhardt, S., & Muggia, F. M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds172 · Cited by 52
Self-citation
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
Secord, A. A., Lewin, S. N., Murphy, C. G., Cecere, S. C., Barquín, A., Gálvez-Montosa, F., Mathews, C. A., Konecny, G. E., Ray-Coquard, I., Oaknin, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.11.011 · Cited by 51
Management and Treatment of Recurrent Epithelial Ovarian Cancer
Armbruster, S. D., Coleman, R. L., & Rauh‐Hain, J. A. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.005 · Cited by 50
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
Lorusso, D., Scambia, G., Amadio, G., Legge, A. D., Pietragalla, A., Vincenzo, R. D., Masciullo, V., Stefano, M. D., Mangili, G., Citterio, G., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.233 · Cited by 49
Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy
Su, X., Zhang, X., Liu, W., Yang, X., An, N., Yang, F., Sun, J., Xing, Y., & Shang, H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.003 · Cited by 47
Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
Galmarini, C. M., D’Incalci, M., & Allavena, P. (2014) · Marine Drugs · doi:10.3390/md12020719 · Cited by 47
Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies
Lyseng-Williamson, K. A., Duggan, S. T., & Keating, G. M. (2013) · BioDrugs · doi:10.1007/s40259-013-0070-1 · Cited by 36
Revisiting the Complexity of the Ovarian Cancer Microenvironment—Clinical Implications for Treatment Strategies
Musrap, N., & Diamandis, E. P. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0353 · Cited by 46
Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer
Webber, K., & Friedlander, M. L. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.11.004 · Cited by 46
Circulating and disseminated tumor cells in ovarian cancer: A systematic review
Romero-Laorden, N., Olmos, D., Fehm, T. N., García-Donás, J., & Díaz-Padilla, I. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.016 · Cited by 45
Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials
Korkmaz, T., Seber, S., & Başaran, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.006 · Cited by 45
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Wang, G., Triantos, S., Maul, R. S., Knoblauch, R. E., McGowan, T., Shalaby, W. S. W., & Coleman, R. L. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.12.043 · Cited by 45
Self-citation
Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Santin, A. D., Vergote, I. B., González-Martı́n, A., Moore, K. N., Oaknin, A., Romero, I., Diab, S., Copeland, L. J., Monk, B. J., Coleman, R. L., et al. (2022) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003927 · Cited by 44
Self-citation
Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
Fotopoulou, C. (2014) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(15)70005-4 · Cited by 44
Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Petit, K., & Biard, J.-F. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313040010 · Cited by 45
State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer
Graybill, W. A. S., Sood, A. K., Monk, B. J., & Coleman, R. L. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.07.008 · Cited by 43
Self-citation
Trabectedin as a chemotherapy option for patients with BRCA deficiency
Monk, B. J., Lorusso, D., Italiano, A., Kaye, S. B., Aracil, M., Tanovı́c, A., & D’Incalci, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.009 · Cited by 43
Self-citation
A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve
Wilson, M. K., Friedlander, M. L., Joly, F., & Oza, A. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0297 · Cited by 38
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation
Edwards, S. J., Barton, S., Thurgar, E., & Trevor, N. (2015) · Health Technology Assessment · doi:10.3310/hta19070 · Cited by 37
The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary
Mabuchi, S., Hisamatsu, T., Kawase, C., Hayashi, M., Sawada, K., Mimura, K., Takahashi, K., Takahashi, T., Kurachi, H., & Kimura, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2987 · Cited by 37
Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
Takahashi, R., Mabuchi, S., Kawano, M., Sasano, T., Matsumoto, Y., Kuroda, H., Kozasa, K., Hashimoto, K., Sawada, K., & Kimura, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151050 · Cited by 37
Liquid biopsy
Gingras, I., Salgado, R., & Ignatiadis, M. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000223 · Cited by 38
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
Lee, C. K., Simes, R. J., Brown, C. S. B., Lord, S. J., Wagner, U. A. G., Plante, M., Vergote, I. B., Pisano, C., Parma, G., Burges, A., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.364 · Cited by 36
Self-citation
Drug Development: Portals of Discovery
Bates, S. E., Amiri‐Kordestani, L., & Giaccone, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1001 · Cited by 36
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Toulmonde, M., Brahmi, M., Giraud, A., Chakiba, C., Bessede, A., Kind, M., Toulza, E., Pulido, M., Albert, S., Guégan, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2258 · Cited by 36
DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
Ovejero-Sánchez, M., González‐Sarmiento, R., & Herrero, A. B. (2023) · Cancers · doi:10.3390/cancers15020448 · Cited by 38
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy
Monk, B. J., Facciabene, A., Brady, W. E., Aghajanian, C. A., Fracasso, P. M., Walker, J. L., Lankes, H. A., Manjarrez, K. L., Danet-Desnoyers, G.-A., Bell‐McGuinn, K. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1453 · Cited by 37
Self-citation
Recent Advances with Liposomes as Drug Carriers
Sriraman, S. K., & Torchilin, V. P. (2014) · Wiley eBooks · doi:10.1002/9781118774052.ch3 · Cited by 36

Authors: Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., Gorbounova, V. A., Ghatage, P., Bidzinski, M., Shen, K., Ngan, H. Y.-S., Vergote, I. B., Nam, J.-H., Park, Y. C., Lebedinsky, C. A., & Poveda, A. M.
Affiliations: University of California, Irvine (US)
From the University of California at Irvine (UCI) and UCI Medical Center, Orange, CA; Columbia University College of Physicians and Surgeons; New York University Hospital, New York, NY; the Royal Marsden Hospital, Surrey, United Kingdom; Gillette Center for Women's Studies, Massachusetts General Hospital, Boston, MA; Antwerp University Hospital, Edegem; University Hospital, Leuven, Belgium; Université Paris Descartes, Assistance Publique Hôpitaux de Paris, Hôpital Hôtel-Dieu, Paris, France; SPBSIH City...
ORCID: Monk, Bradley J.
Herzog, Thomas J.
Vermorken, Jan B.
Muggia, Franco M.
Lisyanskaya, Alla S.
Ghatage, Prafull
Shen, Keng
Vergote, Ignace B.
Nam, Joo-Hyun
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2010-07-01
Volume: 28
Issue: 19
Pages: 3107-3114
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.25.4037
OpenAlex: W2125064537
Cited by: 395
References: 30
Citations by year: 2026: 2 · 2025: 4 · 2024: 9 · 2023: 10 · 2022: 17 · 2021: 25 · 2020: 18 · 2019: 13 · 2018: 25 · 2017: 41 · 2016: 26 · 2015: 32 · 2014: 37 · 2013: 40 · 2012: 37
FWCI: 51.61
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: trabectedin, pegylated liposomal doxorubicin, recurrent ovarian cancer, second-line chemotherapy, platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, progression-free survival, overall response rate, neutropenia, transaminase elevation, hand-foot syndrome, mucositis
MeSH terms: Trabectedin, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dioxoles, Doxorubicin, Drug Administration Schedule, Female, Humans, Leukopenia, Middle Aged, Neoplasm Recurrence, Local, Neutropenia, Ovarian Neoplasms, Polyethylene Glycols, Stomatitis, Multivariate Analysis, Treatment Outcome, Tetrahydroisoquinolines, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks